PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
73.31
+2.46 (3.47%)
At close: Aug 7, 2026, 4:00 PM EDT
72.00
-1.31 (-1.79%)
After-hours: Aug 7, 2026, 7:34 PM EDT
PTC Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, PTC Therapeutics stock has a consensus rating of "Buy" and an average price target of $97.86. The average 1-year stock price forecast is 33.49% higher than the current stock price, while the lowest is $70 (-4.52%) and the highest is $130 (+77.33%).
Price Target: $97.86 (+33.49%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 7 | 7 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 4 | 5 | 5 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 14 | 15 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $120 | Buy | Maintains | $120 | +63.69% | Aug 3, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $130 | Buy | Maintains | $130 | +77.33% | Jul 31, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $85 | Hold | Maintains | $85 | +15.95% | Jul 31, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $70 | Sell | Maintains | $70 | -4.52% | Jul 31, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $93 → $104 | Buy | Maintains | $93 → $104 | +41.86% | Jul 31, 2026 |
Financial Forecast
Revenue This Year
1.26B
from 1.73B
Decreased by -27.00%
Revenue Next Year
1.36B
from 1.26B
Increased by 7.79%
EPS This Year
1.60
from 7.62
Decreased by -79.05%
EPS Next Year
2.50
from 1.60
Increased by 56.58%
EPS and Forward PE are based on non-GAAP adjusted numbers.